Presidio Medical is developing a neuromodulation platform utilizing Ultra Low Frequency (ULF™) current waveforms to inhibit pain signals by inactivating sodium channels in neurons. This technology aims to provide a reversible treatment for chronic pain, addressing the limitations of existing therapies and reducing reliance on opioids.
Funding
$72M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
DFounders
Product
Problem
Chronic pain affects approximately 50 million individuals in the US, resulting in significant treatment and economic costs. Existing therapies, including opioids, often have limitations and can lead to mortality, highlighting the need for alternative treatments.
Solution
Presidio Medical is developing a neuromodulation platform that utilizes Ultra Low Frequency (ULF™) current waveforms to provide a reversible treatment for chronic pain. The ULF™ neuromodulation inhibits pain signals by inactivating sodium channels in neurons, offering a unique mechanism of action compared to existing Spinal Cord Stimulation (SCS) technologies that activate neurons. In clinical trials, patients experienced a significant reduction in back pain without paresthesia or loss of sensation. The technology aims to address diseases of undesired neural activity and provide a better therapy for chronic pain.
Target Audience
The primary target audience includes individuals suffering from chronic pain and healthcare providers seeking alternative, non-opioid pain management solutions.
Features
- Novel Ultra Low Frequency (ULF™) neuromodulation to inhibit pain signals
- Reversible inhibition of pain neurons through sodium channel inactivation
- Demonstrated significant decrease in back pain in clinical trials
- Patients experienced pain relief without paresthesia, or loss of sensation or function
- Addresses the limitations of existing therapies and reduces reliance on opioids